| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6420d04b0d68f339771080e32bd0fbc9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96447
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2405-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 |
| filingDate |
1993-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1999-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e30a5393c1ecbe0273c7682f2ca9dd7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79d24af1ea4255188bb33cef985fe633 |
| publicationDate |
1999-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0642352-B1 |
| titleOfInvention |
TRUNCATED TISSUE FACTOR AND FVIIa OR FVII ACTIVATOR FOR BLOOD COAGULATION |
| abstract |
It has been discovered that it is possible to administer truncated tissue factor (not having the transmembrane region) (tTF) in combination with factor VIIa (FVIIa) or an activator of endogenous factor VII to treat bleeding disorders such as those resulting from hemophilia or cirrhosis of the liver. The tTF is administered to produce up to 10 mu g tTF/ml of plasma. The FVIIa or FVII activator is administered to produce levels of between 40 ng FVIIa/ml and 700 ng FVIIa/ml of plasma. The effective dosages of both tTF and FVIIa/factor VII activator are significantly and surprisingly less than the administration of either alone to stop bleeding. Examples demonstrate safety and efficacy in normal and hemophilic dogs. |
| priorityDate |
1992-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |